Drug · DIN 02491559
ULTOMIRIS
300 MG/30 ML SINGLE-USE
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since August 26, 2025; first marketed September 9, 2021.
- Drug Identification Number (DIN)
- 02491559
- Company (DIN owner)
- Alexion Pharma GmbhBaar, --, Switzerland
- Schedule
- Schedule d; Prescription
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Ravulizumab L04AJ02
- Class
- Human
- Record last updated
- August 12, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RAVULIZUMAB | 10 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 28, 2019: NOC 22577New Drug Submission (NDS)
Other DINs named ULTOMIRIS
- DIN 02533448 · Marketed
- DIN 02533456 · Marketed